



**OFFICER'S CERTIFICATE (AMENDED)**

*Pursuant to Section 2.20 of National Instrument 54-101 —  
Communication with Beneficial Owners of Securities of a Reporting Issuer*

**TO:**

Alberta Securities Commission  
British Columbia Securities Commission  
Ontario Securities Commission  
TSX Venture Exchange

**Re: September 5, 2025 Annual General Meeting of Shareholders (the “Meeting”) of Thiogenesis Therapeutics, Corp. (the “Company”) Abridging Time pursuant Section 2.20 with respect to Section 2.2(1) of National Instrument 54-101 (“NI 54-101”)**

I, Patrice Rioux, Chief Executive Officer of the Company, report and certify on behalf of the Company, as an officer of the Company and not in my personal capacity, that, as of the date of this Certificate:

- (a) the Company has arranged to have proxy-related materials for the Meeting sent in compliance with NI 54-101 to all beneficial owners of common shares of the Company at least 21 days before the date fixed for the Meeting;
- (b) the Company has arranged to have carried out all of the requirements of NI 54-101 in addition to those described in subparagraph (a); and
- (c) the Company is relying upon section 2.20 of NI 54-101 in abridging the times prescribed in section 2.2(1) of NI 54-101.

Dated this 28th day of July 2025.

**THIOGENESIS THERAPEUTICS, CORP.**

Per: */s/ Patrice P. Rioux*  
Patrice P. Rioux  
Chief Executive Officer